Olympus Announces CMS Valuation and Reimbursement Rates for New ESD CPT Codes

Olympus secures final U.S. Medicare codes for ESD, effective January 2027.

What the company is saying

Olympus Corporation is announcing that the U.S. Centers for Medicare & Medicaid Services (CMS) has published final valuations and reimbursement rates for Endoscopic Submucosal Dissection (ESD) Category I CPT codes, with implementation set for January 1, 2027. The company frames this as a regulatory milestone that enables standardized billing and reporting for ESD procedures in both upper (CPT 43498) and lower (CPT 45991) gastrointestinal tracts. Olympus emphasizes ESD as a minimally invasive, organ-preserving procedure for cancerous and pre-cancerous GI lesions, highlighting both clinical value and procedural complexity. The announcement features remarks from Dr. Joo Ha Hwang of Stanford University, who underscores the diagnostic and therapeutic benefits of ESD, and from Olympus executives Racho Strauven and Keith Boettiger, who stress the importance of appropriate reimbursement and Olympus’s ongoing investment in education and technology. The tone is confident, positioning Olympus as a pioneer in ESD, especially referencing its role in Japan and its commitment to expanding U.S. adoption through continued support.

What the data suggests

The announcement confirms that final Medicare reimbursement rates and CPT codes for ESD have been established and will take effect on January 1, 2027. Two distinct codes—CPT 43498 for upper GI ESD and CPT 45991 for lower GI ESD—will allow for more precise billing and reporting across all care settings in the U.S. The codes recognize the clinical complexity and physician work involved in ESD, but the actual reimbursement amounts are not disclosed. No financial data, revenue projections, or adoption targets are provided, and there is no quantitative evidence of the impact on Olympus’s business or the broader market. The only hard facts are the regulatory milestone, the effective date, and the procedural definitions. The rest of the narrative is qualitative, focusing on potential clinical benefits and Olympus’s intention to invest further in education and technology.

Analysis

The announcement is positive in tone, highlighting the finalization of Medicare reimbursement rates and CPT codes for ESD procedures, which is a concrete regulatory milestone. However, the majority of the claims with potential financial or operational impact are forward-looking, such as Olympus's commitment to continued investment in education and technology to expand ESD adoption. The actual reimbursement rates, projected revenue, or financial impact are not disclosed, and the effective date for the new codes is over a year away (January 1, 2027), placing the realization of benefits in the long-term category. The mention of ongoing investment signals capital intensity, but with no immediate earnings impact or quantifiable benefit. The narrative is somewhat inflated by emphasizing Olympus's pioneering role and future investments without providing supporting data or timelines for these initiatives.

Risk flags

• ●There is no disclosure of the actual Medicare reimbursement rates, leaving uncertainty about the financial attractiveness of ESD for providers and the potential market impact for Olympus. Without these figures, the commercial significance of the milestone cannot be assessed.
• ●The effective date is more than a year away, introducing execution risk related to provider adoption, training, and potential regulatory or policy changes before implementation. Delays or changes in CMS policy could affect the anticipated benefits.
• ●The announcement relies heavily on qualitative claims about clinical value and Olympus’s pioneering role, but provides no data on expected uptake, market size, or revenue impact. This lack of quantifiable targets or projections increases uncertainty for investors.

Bottom line

Olympus has achieved a key regulatory milestone by securing final U.S. Medicare reimbursement codes for ESD procedures, with the new codes and rates set to take effect on January 1, 2027. This move should facilitate broader adoption of ESD in the U.S. by enabling standardized billing and potentially improving access for patients. However, the absence of disclosed reimbursement amounts or any quantification of expected financial impact means investors cannot gauge the commercial upside at this stage. The timeline to value is long, with benefits unlikely to appear before 2027, and there are execution risks around provider adoption and policy stability. For now, this is a strategic positioning win for Olympus, but investors will need to see actual reimbursement figures and early adoption data to assess the real impact. The most important takeaway is that Olympus has cleared a regulatory hurdle, but the financial implications remain undefined.

Announcement summary

(FSE:OLY1) Olympus Corporation announced the publication of final valuations and CY2027 Medicare reimbursement rates for Endoscopic Submucosal Dissection (ESD) Category I Current Procedural Terminology (CPT) codes by the U.S. Centers for Medicare & Medicaid Services (CMS). The new rates and codes will take effect on January 1, 2027. The newly designated ESD procedure codes allow physicians to report ESD in all sites of service and enable outpatient facilities to separately bill and report upper and lower ESD procedures. The two separate codes are CPT 43498 for ESD of the upper gastrointestinal tract, including mucosal closure when performed, and CPT 45991 for ESD of the lower gastrointestinal tract, including mucosal closure when performed. ESD is described as a minimally invasive endoscopic procedure used to treat cancerous and pre-cancerous lesions of the GI tract, allowing removal of abnormal tissue through an endoscope without external incisions. For select patients, ESD may offer a minimally invasive alternative to more extensive surgery, potentially preserving the affected organ. Dr. Joo Ha Hwang, M.D., Ph.D., Chief of the Division of Gastroenterology and Hepatology at Stanford University, stated that ESD can accomplish both diagnosis and treatment in a single, organ-preserving procedure, and may allow appropriately selected patients to avoid major surgery. The final valuations are said to reflect the clinical complexity and physician work involved in ESD. Racho Strauven, Senior Vice President, Health Economics and Market Access at Olympus Corporation, commented that the new rates recognize the skill and clinical expertise required for ESD and, together with standardized coding, help address reimbursement considerations for establishing ESD programs. Olympus Corporation highlighted that ESD is central to its strategy of advancing endoscopy-enabled care, aiming for earlier and less invasive detection and treatment of GI disease. Keith Boettiger, Executive Officer and Head of the Gastrointestinal Solutions Division at Olympus Corporation, noted that Olympus helped pioneer ESD alongside physicians in Japan and will continue to invest in professional education, hands-on training, and advanced technologies to support U.S. clinicians in bringing ESD to more patients.

Disagree with this article?